| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Over the last 12 months, insiders at Cognition Therapeutics, Inc. have bought $0 and sold $0 worth of Cognition Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cognition Therapeutics, Inc. have bought $3.76M and sold $4,818 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 38,851 shares for transaction amount of $30,001 was made by Ricciardi Lisa (CEO & President) on 2025‑01‑31.
| 2025-01-31 | Ricciardi Lisa | CEO & President | 38,851 0.094% | $0.77 | $30,001 | +1.69% | ||
| 2024-03-14 | Ricciardi Lisa | CEO & President | 5,700 0.0172% | $1.75 | $9,975 | -60.21% | ||
| 2022-11-29 | RICHSTONE ELLEN B | director | 10,000 0.0453% | $2.65 | $26,550 | -29.84% | ||
| 2022-11-28 | Kreis Leslie W. | director | 16,064 0.0706% | $2.65 | $42,565 | -31.76% | ||
| 2022-11-28 | Fletcher Aaron G.L. | director | 16,064 0.0706% | $2.65 | $42,565 | -31.76% | ||
| 2022-11-16 | Kreis Leslie W. | director | 71,000 0.3069% | $1.40 | $99,400 | +27.74% | ||
| 2022-11-16 | Fletcher Aaron G.L. | director | 71,000 0.3069% | $1.40 | $99,400 | +27.74% | ||
| 2022-11-15 | Kreis Leslie W. | director | 1.5M 5.2511% | $1.20 | $1.8M | +20.69% | ||
| 2022-11-15 | Fletcher Aaron G.L. | director | 1.5M 5.2511% | $1.20 | $1.8M | +20.69% | ||
| 2022-11-15 | Wallace Peggy | director | 12,500 0.0438% | $1.20 | $15,000 | +20.69% | ||
| 2022-11-15 | Ricciardi Lisa | CEO & President | 12,000 0.0455% | $1.30 | $15,600 | +20.69% | ||
| 2021-10-13 | Sale | Ogden CAP Associates, LLC | 10 percent owner | 74.05 0.0014% | $12.00 | $889 | -76.39% | |
| 2021-10-13 | Sale | Golden Seeds Cognition Therapeutics LLC | 10 percent owner | 33.09 0.0006% | $12.00 | $397 | -76.39% | |
| 2021-10-13 | Sale | Breedlove Mark H. | director | 23.48 0.0004% | $12.00 | $282 | -76.39% | |
| 2021-10-13 | Sale | Fletcher Aaron G.L. | director | 180.56 0.0034% | $12.00 | $2,167 | -76.39% | |
| 2021-10-13 | Sale | BIOS Memory SPV I, LP | 10 percent owner | 90.28 0.0017% | $12.00 | $1,083 | -76.39% | |
| 2021-10-13 | Fletcher Aaron G.L. | director | 380,000 7.2005% | $12.00 | $4.56M | -76.39% | ||
| 2021-10-13 | BIOS Memory SPV I, LP | 10 percent owner | 190,000 3.6003% | $12.00 | $2.28M | -76.39% | ||
| 2021-10-13 | Ricciardi Lisa | CEO & President | 25,000 0.4737% | $12.00 | $300,000 | -76.39% | ||
| 2021-10-13 | O'Brien James Michael | Chief Financial Officer | 10,000 0.1895% | $12.00 | $120,000 | -76.39% |
| Ogden CAP Associates, LLC | 10 percent owner | 2210377 3.004% | $2.28M | 0 | 1 | |
| Golden Seeds Cognition Therapeutics LLC | 10 percent owner | 2177985 2.9599% | $2.24M | 0 | 1 | |
| Fletcher Aaron G.L. | director | 2021906 2.7478% | $2.08M | 4 | 1 | <0.0001% |
| Kreis Leslie W. | director | 2021906 2.7478% | $2.08M | 3 | 0 | +5.55% |
| BIOS Memory SPV I, LP | 10 percent owner | 899905 1.223% | $926,902.15 | 1 | 1 | <0.0001% |
| Breedlove Mark H. | director | 404439 0.5496% | $416,572.17 | 0 | 1 | |
| Ricciardi Lisa | CEO & President | 38851 0.0528% | $40,016.53 | 4 | 0 | <0.0001% |
| Wallace Peggy | director | 37961 0.0516% | $39,099.83 | 2 | 0 | <0.0001% |
| RICHSTONE ELLEN B | director | 10000 0.0136% | $10,300.00 | 1 | 0 | <0.0001% |
| O'Brien James Michael | Chief Financial Officer | 5000 0.0068% | $5,150.00 | 1 | 0 | <0.0001% |
$1,695,621 | 55 | 17.90% | $59.7M | |
$77,146,704 | 43 | 13.28% | $92.68M | |
$909,129 | 37 | 42.19% | $81.51M | |
$38,601,028 | 29 | 1.18% | $78.1M | |
$27,151,286 | 27 | -16.85% | $63.56M | |
$1,602,584 | 20 | 15.26% | $66.84M | |
$33,128,160 | 18 | -13.64% | $82.7M | |
$20,234,041 | 17 | 2.09% | $74.87M | |
Cognition Therapeutics, Inc. (CGTX) | $11,267,080 | 15 | -22.36% | $75.79M |
$3,763,566 | 15 | -21.70% | $61.11M | |
$17,741,707 | 13 | 30.23% | $85.3M | |
$32,684,649 | 8 | -15.84% | $69.98M | |
$106,599,960 | 6 | -7.63% | $87.27M | |
$45,000,000 | 6 | -31.22% | $60.16M | |
$110,013 | 5 | 6.58% | $79.59M | |
$762,555 | 4 | -34.52% | $67.32M | |
$401,951 | 4 | 57.41% | $71.65M | |
$193,889 | 4 | 73.66% | $80.74M | |
$19,175,155 | 2 | 40.00% | $82.59M |
| Increased Positions | 32 | +41.56% | 3M | +13.48% |
| Decreased Positions | 24 | -31.17% | 3M | -13.31% |
| New Positions | 16 | New | 1M | New |
| Sold Out Positions | 8 | Sold Out | 1M | Sold Out |
| Total Postitions | 85 | +10.39% | 21M | +0.17% |
| Bios Capital Management, Lp | $8,820.00 | 6.82% | 6M | 0 | 0% | 2025-09-30 |
| Davenport & Co Llc | $3,953.00 | 3.06% | 2.69M | +3M | New | 2025-09-30 |
| Vanguard Group Inc | $3,942.00 | 3.05% | 2.68M | +1M | +105.59% | 2025-09-30 |
| Tang Capital Management Llc | $1,764.00 | 1.36% | 1.2M | +1M | New | 2025-09-30 |
| Chescapmanager Llc | $1,466.00 | 1.13% | 997,029 | +493,770 | +98.11% | 2025-09-30 |
| Blackrock, Inc. | $1,424.00 | 1.1% | 968,699 | +891,844 | +1,160.42% | 2025-09-30 |
| Jane Street Group, Llc | $1,361.00 | 1.05% | 926,150 | +912,936 | +6,908.85% | 2025-09-30 |
| Renaissance Technologies Llc | $1,049.00 | 0.81% | 713,500 | +617,100 | +640.14% | 2025-09-30 |
| Geode Capital Management, Llc | $1,048.00 | 0.81% | 712,727 | +344,007 | +93.3% | 2025-09-30 |
| Hilton Capital Management, Llc | $854.00 | 0.66% | 581,150 | +581,150 | New | 2025-09-30 |